BRCA2-related cancer predisposition

This early-phase trial tested a combination of three drugs—olaparib, palbociclib, and fulvestrant—in 9 people with BRCA-mutated, hormone-positive, HER2-negative metastatic breast cancer. The main goal was to see if the combination is safe. Researchers also looked at how long the …

This completed study enrolled 377 individuals and families with a high risk of breast or ovarian cancer due to known or suspected genetic factors. Researchers collected medical records, questionnaires, and biological samples to better understand the disease's natural history and …

Researchers want to know how common a BRCA2 gene mutation is among people diagnosed with breast cancer on Reunion Island. Earlier work found that more than half of patients there with a BRCA mutation carry a variant specific to the island's population. This study collects blood s…

This study tested whether a 'Disclosure Toolkit'—including a family letter, a chatbot, and a website—helps people with BRCA1 or BRCA2 mutations share their genetic test results with at-risk relatives. Researchers enrolled 52 participants to see if the toolkit improves communicati…

This study tested whether a short video sent by text message could help people with BRCA gene mutations encourage their relatives to get tested. Fifty-eight participants completed the trial. The goal was to see if the video made it easier to share important health information wit…